Prinomastat is primarily investigated for its application in cancer treatment, specifically as a matrix metalloproteinase (MMP) inhibitor. It works by blocking the activity of MMP enzymes, which are involved in tumor growth, invasion, and metastasis. This makes it a potential therapeutic agent for inhibiting the spread of cancer cells in various types of tumors. Clinical studies have explored its use in treating cancers such as prostate, lung, and brain tumors. However, its development has faced challenges due to limited efficacy in some trials and side effects, leading to further research to optimize its use in combination therapies or targeted treatments.